The Research, Scholarship, and Artistic Achievement Awards nomination deadline has been extended to May 31, 2024. Click here for more information.

Compositions for the prevention and treatment of HIV with mesenchymal stem cells


Tulane University is actively seeking commercial entities to further develop and commercialize compositions to treat HIV using mesenchymal stem cells that express HIV antiviral fusion inhibitors.


MSCs expressing antiviral fusion inhibitors may be used to prevent HIV infection pre-exposure or post-exposure. MSC compositions may be used to treat HIV infection alone or in combination with anti-retroviral therapy. Multiple antiviral fusion inhibitors may be used in the MSC compositions, including peptide inhibitors and neutralizing antibodies. AdvantagesMSC compositions provide long-term, continuous expression of HIV inhibitors. Side effects associated with currently-available HIV inhibitors are avoided. MSC compositions may use autologous or allogeneic stem cells.

Current Work

This technology has been tested extensively in the lab, including infection/inhibition assays and MSC differentiation assays.

Available For

Exclusive License in a Field
Non-exclusive License
Scientific Collaboration

For more information, please contact: